JNJ 63733657

Drug Profile

JNJ 63733657

Alternative Names: JNJ63733657

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development
  • Class Antibodies; Antidementias
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 02 Jan 2018 Phase-I clinical trials in Alzheimer's disease in Belgium (IV) (NCT03375697)
  • 27 Dec 2017 Janssen Research & Development plans a phase I trial in healthy subjects and patients with Alzheimer's disease (In adults, In the elderly) in Belgium and Netherlands (IV) in January 2018 (NCT03375697)
  • 27 Dec 2017 Early research in Alzheimer's disease in Belgium (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top